US 12,215,085 B2
Cholinesterase inhibitor polymorph and application thereof
Tonghui Wang, Changchun (CN); Ju Zhang, Changchun (CN); Lihua Wang, Changchun (CN); Depu Wang, Changchun (CN); Yaxin Zhang, Changchun (CN); Qinghua Yu, Changchun (CN); Qi Zhang, Changchun (CN); and Mingze Li, Changchun (CN)
Assigned to CHANGCHUN HUAYUAN HIGH-SCIENCE AND TECHNOLOGY CO., LTD., Changchun (CN); and JIANGSU SHENERYANG HIGH-SCIENCE AND TECHNOLOGY CO., LTD., Taizhou (CN)
Appl. No. 17/424,699
Filed by CHANGCHUN HUAYUAN HIGH-SCIENCE AND TECHNOLOGY CO., Changchun (CN); and JIANGSU SHENERYANG HIGH-SCIENCE AND TECHNOLOGY CO., Taizhou (CN)
PCT Filed Jan. 21, 2020, PCT No. PCT/CN2020/073389
§ 371(c)(1), (2) Date Jul. 21, 2021,
PCT Pub. No. WO2020/156360, PCT Pub. Date Aug. 6, 2020.
Claims priority of application No. 201910100045.9 (CN), filed on Jan. 31, 2019.
Prior Publication US 2022/0227712 A1, Jul. 21, 2022
Int. Cl. C07D 219/10 (2006.01); A61P 25/28 (2006.01)
CPC C07D 219/10 (2013.01) [A61P 25/28 (2018.01); C07B 2200/13 (2013.01)] 20 Claims
 
1. A crystal form of octahydroaminoacridine succinate, wherein said crystal form is any one of the following crystal forms:
Crystal Form A, characterized by main characteristic X-ray powder diffraction peaks at the corresponding positions of 2θ values of 8.8°±0.2°, 16.4°±0.2°, 23.2°±0.2°;
Crystal Form C, characterized by main characteristic X-ray powder diffraction peaks at the corresponding positions of 2θ values of 8.0°±0.2°, 24.1°±0.2°, 21.7°±0.2°;
Crystal Form F, characterized by main characteristic X-ray powder diffraction peaks at the corresponding positions of 2θ values of 21.3°±0.2°, 7.1°±0.2°, 26.3°±0.2°.